Eli Lilly is participating in a new investment fund which will focus primarily on early-stage drug development opportunities in Canada as a whole and Quebec in particular.
The fund, which will be operated by investment investment group TVM Capital, will have an initial size of $150 million. As well as Lilly, other backers include Teralys Capital (which is putting in $65 million), BDC Venture Capital, Fondaction and Advantus Capital Management.
{iframe}http://www.pharmatimes.com/Article/12-05-29/Lilly_invests_in_150_million_Canada_life_sciences_fund.aspx{/iframe}